101 related articles for article (PubMed ID: 26344293)
1. The effect of mechanical grinding on the formation, crystalline changes and dissolution behaviour of the inclusion complex of telmisartan and β-cyclodextrins.
Borba PA; Pinotti M; Andrade GR; da Costa NB; Olchanheski Junior LR; Fernandes D; de Campos CE; Stulzer HK
Carbohydr Polym; 2015 Nov; 133():373-83. PubMed ID: 26344293
[TBL] [Abstract][Full Text] [Related]
2. Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: improved solubility and reduced pharmacokinetic variability.
Sangwai M; Vavia P
Int J Pharm; 2013 Sep; 453(2):423-32. PubMed ID: 22935741
[TBL] [Abstract][Full Text] [Related]
3. Sodium alginate as a potential carrier in solid dispersion formulations to enhance dissolution rate and apparent water solubility of BCS II drugs.
Borba PAA; Pinotti M; de Campos CEM; Pezzini BR; Stulzer HK
Carbohydr Polym; 2016 Feb; 137():350-359. PubMed ID: 26686139
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan complex augments solubility, dissolution and drug delivery in prostate cancer cells.
Kaur M; Bhatia RK; Pissurlenkar RR; Coutinho EC; Jain UK; Katare OP; Chandra R; Madan J
Carbohydr Polym; 2014 Jan; 101():614-22. PubMed ID: 24299818
[TBL] [Abstract][Full Text] [Related]
5. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
Al Omari AA; Al Omari MM; Badwan AA; Al-Sou'od KA
J Pharm Biomed Anal; 2011 Feb; 54(3):503-9. PubMed ID: 20971593
[TBL] [Abstract][Full Text] [Related]
6. Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective.
Dukeck R; Sieger P; Karmwar P
Eur J Pharm Sci; 2013 Jul; 49(4):723-31. PubMed ID: 23684913
[TBL] [Abstract][Full Text] [Related]
7. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
8. Utility of cyclodextrins in the formulation of genistein part 1. Preparation and physicochemical properties of genistein complexes with native cyclodextrins.
Daruházi AE; Szente L; Balogh B; Mátyus P; Béni S; Takács M; Gergely A; Horváth P; Szoke E; Lemberkovics E
J Pharm Biomed Anal; 2008 Nov; 48(3):636-40. PubMed ID: 18757150
[TBL] [Abstract][Full Text] [Related]
9. Improved pH-dependent drug release and oral exposure of telmisartan, a poorly soluble drug through the formation of drug-aminoclay complex.
Yang L; Shao Y; Han HK
Int J Pharm; 2014 Aug; 471(1-2):258-63. PubMed ID: 24834880
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutical characterization of praziquantel cocrystals and cyclodextrin complexes prepared by grinding.
Cugovčan M; Jablan J; Lovrić J; Cinčić D; Galić N; Jug M
J Pharm Biomed Anal; 2017 Apr; 137():42-53. PubMed ID: 28092854
[TBL] [Abstract][Full Text] [Related]
11. Novel oral formulation approach for poorly water-soluble drug using lipocalin-type prostaglandin D synthase.
Mizoguchi M; Nakatsuji M; Inoue H; Yamaguchi K; Sakamoto A; Wada K; Inui T
Eur J Pharm Sci; 2015 Jul; 74():77-85. PubMed ID: 25906910
[TBL] [Abstract][Full Text] [Related]
12. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
[TBL] [Abstract][Full Text] [Related]
13. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
Miro A; Quaglia F; Sorrentino U; La Rotonda MI; D'Emmanuele Di Villa Bianca R; Sorrentino R
Eur J Pharm Sci; 2004 Sep; 23(1):57-64. PubMed ID: 15324923
[TBL] [Abstract][Full Text] [Related]
14. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
[TBL] [Abstract][Full Text] [Related]
15. Inclusion complexes of fluorofenidone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
Wang S; Ding Y; Yao Y
Drug Dev Ind Pharm; 2009 Jul; 35(7):808-13. PubMed ID: 19337873
[TBL] [Abstract][Full Text] [Related]
16. Molecular encapsulation of rifampicin as an inclusion complex of hydroxypropyl-β-cyclodextrin: design; characterization and in vitro dissolution.
He D; Deng P; Yang L; Tan Q; Liu J; Yang M; Zhang J
Colloids Surf B Biointerfaces; 2013 Mar; 103():580-5. PubMed ID: 23261583
[TBL] [Abstract][Full Text] [Related]
17. Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration.
Nekkanti V; Karatgi P; Paruchuri S; Pillai R
Drug Deliv; 2011 May; 18(4):294-303. PubMed ID: 21214430
[TBL] [Abstract][Full Text] [Related]
18. DSC, X-ray and FTIR studies of a gemfibrozil/dimethyl-β-cyclodextrin inclusion complex produced by co-grinding.
Aigner Z; Berkesi O; Farkas G; Szabó-Révész P
J Pharm Biomed Anal; 2012 Jan; 57():62-7. PubMed ID: 21920691
[TBL] [Abstract][Full Text] [Related]
19. Improvement on dissolution rate of inclusion complex of Rifabutin drug with β-cyclodextrin.
Shanmuga Priya A; Sivakamavalli J; Vaseeharan B; Stalin T
Int J Biol Macromol; 2013 Nov; 62():472-80. PubMed ID: 24076034
[TBL] [Abstract][Full Text] [Related]
20. Molecular simulation of hydroxypropyl-beta-cyclodextrin with hydrophobic selective Cox-II chemopreventive agent using host-guest phenomena.
Sinha VR; Nanda A; Chadha R; Goel H
Acta Pol Pharm; 2011; 68(4):585-92. PubMed ID: 21796941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
